Abstract #1121: A Next-Generation Gene Expression Classifier for Cytologically Indeterminate Thyroid Nodules Derived from a Novel Sequencing Platform and Machine Learning Algorithms with Improved Clinical Specificity: Interim Analysis

Ladenson, Paul W.; Angell, Trevor E.; Babiarz, Joshua E.; Barth, Neil M.; Blevins, Thomas; Duh, Quan‐Yang; Ghossein, Ronald; Harrell, R. Mack; Huang, Jing; Imtiaz, Urooj; Kennedy, Giulia C.; Kim, Su Yeon; Kloos, Richard T.; LiVolsi, Virginia A.; Randolph, Gregory W.; Sadow, Peter M.; Shanik, Michael H.; Sosa, Julie Ann; Traweek, S. Thomas; Walsh, Paul; Whitney, Duncan; Yeh, Ming‐Yang; Patel, Kepal N.

doi:10.1016/s1530-891x(20)44248-x

Endocrine Practice

2017

DOI: 10.1016/s1530-891x(20)44248-x

|View full text |Cite

Abstract #1121: A Next-Generation Gene Expression Classifier for Cytologically Indeterminate Thyroid Nodules Derived from a Novel Sequencing Platform and Machine Learning Algorithms with Improved Clinical Specificity: Interim Analysis

Paul W. Ladenson¹,

Trevor E. Angell²,

Joshua E. Babiarz³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2018

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

A retrospective analysis of the performance of the RosettaGX^® Reveal™ thyroid miRNA and the Afirma Gene Expression Classifiers in a cohort of cytologically indeterminate thyroid nodules

Walts

Sacks

et al. 2018

Diagnostic Cytopathology

View full text Add to dashboard Cite

Background Molecular tests are increasingly used to triage cytologically indeterminate thyroid nodules for surgery and/or follow‐up. We retrospectively compared the performance of the Afirma Gene Expression Classifier (AGEC) with that of the more recently developed RosettaGX® Reveal™ miRNA Classifier (Reveal) in a cohort of Bethesda III–V thyroid FNAs with surgical follow‐up. Design Eighty‐one samples (54 Bethesda III, 26 Bethesda IV, 1 Bethesda V) with available AGEC (74 AGEC‐SUSP and 7 AGEC‐BENIGN) and surgical pathology results were studied from three academic centers. Reveal was performed in a blinded fashion. Results The final diagnoses were benign/NIFTP (n = 63) and malignant (n = 18). The overall “correct” rate was 64.2% for Reveal and 28.4% for AGEC (P = 1.4e‐6). The specificity of Reveal was 60.3%, compared with 9.5% for AGEC (P = 2.1e‐9). Among the 18 malignant cases, 77.8% and 94.4% were correctly classified as suspicious by Reveal and AGEC, respectively (P = 0.2). In the FLUS and the FN group, the specificity of AGEC was lower than the specificity of Reveal. Whether the 7 NIFTP in our study were considered benign or malignant, specificity and PPV of Reveal were higher than those of AGEC. Reveal also outperformed AGEC in correctly classifying the 26 benign Hürthle lesions studied (P = 7.6e‐5). Conclusion Reveal outperformed AGEC in this cohort, whether NIFTP is considered benign or malignant, and in Hürthle lesions. Reveal has the potential to reduce the number of unnecessary resections in patients with indeterminate thyroid cytology. Based on our findings and the practical advantages offered by Reveal methodology, large prospective studies are warranted. Diagn. Cytopathol.

show abstract

A retrospective analysis of the performance of the RosettaGX^® Reveal™ thyroid miRNA and the Afirma Gene Expression Classifiers in a cohort of cytologically indeterminate thyroid nodules

Walts

Sacks

et al. 2018

Diagnostic Cytopathology

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Abstract #1121: A Next-Generation Gene Expression Classifier for Cytologically Indeterminate Thyroid Nodules Derived from a Novel Sequencing Platform and Machine Learning Algorithms with Improved Clinical Specificity: Interim Analysis

Cited by 1 publication

References 0 publications

A retrospective analysis of the performance of the RosettaGX^® Reveal™ thyroid miRNA and the Afirma Gene Expression Classifiers in a cohort of cytologically indeterminate thyroid nodules

A retrospective analysis of the performance of the RosettaGX^® Reveal™ thyroid miRNA and the Afirma Gene Expression Classifiers in a cohort of cytologically indeterminate thyroid nodules

Contact Info

Product

Resources

About

Abstract #1121: A Next-Generation Gene Expression Classifier for Cytologically Indeterminate Thyroid Nodules Derived from a Novel Sequencing Platform and Machine Learning Algorithms with Improved Clinical Specificity: Interim Analysis

Cited by 1 publication

References 0 publications

A retrospective analysis of the performance of the RosettaGX® Reveal™ thyroid miRNA and the Afirma Gene Expression Classifiers in a cohort of cytologically indeterminate thyroid nodules

A retrospective analysis of the performance of the RosettaGX® Reveal™ thyroid miRNA and the Afirma Gene Expression Classifiers in a cohort of cytologically indeterminate thyroid nodules

Contact Info

Product

Resources

About

A retrospective analysis of the performance of the RosettaGX^® Reveal™ thyroid miRNA and the Afirma Gene Expression Classifiers in a cohort of cytologically indeterminate thyroid nodules

A retrospective analysis of the performance of the RosettaGX^® Reveal™ thyroid miRNA and the Afirma Gene Expression Classifiers in a cohort of cytologically indeterminate thyroid nodules